---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102383"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:13:13.327309+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q2 net sales $203.1M (+2.3%); adj. EBITDA $20.6M; positive FCF; reaffirms FY25 guide

## Summary
- Pro forma net sales (ex-M6) $200.7M, +3.5% constant currency; net loss $(14.1)M vs $(33.4)M prior year.
- Non-GAAP pro forma adjusted EBITDA $20.6M (10.3% margin), up 24% YoY; six straight quarters of margin expansion.
- Free cash flow positive $4.5M in Q2; cash, equivalents and restricted cash $68.7M.
- U.S. Spine Fixation sales +5% (volume +7%); BGT Fracture +7%; U.S. Orthopedics +28%.
- FY2025 guidance reaffirmed: pro forma net sales $808-816M, adj. EBITDA $82-86M, positive FCF.

## SEC filing metadata
- accession: 0000950170-25-102383
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017025102383/0000950170-25-102383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017025102383/ofix-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102383
- JSON: https://secwatch.observer/filing/0000950170-25-102383.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.